Back to Search
Start Over
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: Part 2.
- Source :
-
Endocrinology and metabolism clinics of North America [Endocrinol Metab Clin North Am] 2023 Mar; Vol. 52 (1), pp. 39-47. Date of Electronic Publication: 2022 Nov 18. - Publication Year :
- 2023
-
Abstract
- Type 2 diabetes is characterized by progressive decline in pancreatic β-cell function. Newer agents, such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and dual incretin agonists, can augment β-cell function and delay the need for additional antihyperglycemics. However, the effect on β-cell function ceases after stopping the medications. When combined with intensive lifestyle modifications, higher doses of GLP-1RA than those used for diabetes treatment can be used to induce weight loss. More research is needed on whether the weight loss achieved with GLP1-RA can be sustained after stopping medication and in turn can sustain diabetes remission.<br />Competing Interests: Disclosure S. Hao and P. Vellanki have no disclosures. G.E. Umpierrez has received unrestricted support for research studies (to Emory University) from AstraZeneca and Dexcom.<br /> (Copyright © 2022 Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1558-4410
- Volume :
- 52
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Endocrinology and metabolism clinics of North America
- Publication Type :
- Academic Journal
- Accession number :
- 36754496
- Full Text :
- https://doi.org/10.1016/j.ecl.2022.07.004